Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0662-3168 · 1 trial · 3 indications
Number of events.
Number of events.
Measure in Percentage (%) change in body weight
Measured in percentage of glycated haemoglobin.
| Arm | Type | Description |
|---|---|---|
| NNC0662-3168 (Test product-A) | EXPERIMENTAL | Participants will receive NNC0662-3168 by subcutaneous injection in Part A to Part D. |
| Placebo matched to NNC0662-3168 (Test product-A) | PLACEBO_COMPARATOR | Participants will receive placebo by subcutaneous injection in Part A to Part C. |
| Product-B | ACTIVE_COMPARATOR | Participants will receive active comparator (product-B) by subcutaneous injection in Part C to Part D. |
| Name | Type | Description |
|---|---|---|
| NNC0662-3168 (Test product-A) | DRUG | NNC0662-3168 is administered subcutaneously. |
| Placebo matched to NNC0662-3168 (Test product-A) | DRUG | Placebo is administered subcutaneously. |
| Active Comparator (Product-B) | DRUG | Active Comparator is administered subcutaneously. |
Inclusion Criteria: Male or female (sex at birth). * Age at the time of signing the informed consent: * For Part A: 18-55 years (both inclusive). * For Part B: 18-55 years (both inclusive). * For Part C: 18-65 years (both inclusive). * For Part D: 18-75 years (both inclusive). Part D : * Diagnos...